<p>隨着全球市場持續波動，亞洲指數在地緣政治緊張局勢和經濟變動中表現出韌性，投資者越來越關注具有強勁增長潛力和顯著內部持股的公司。在這種背景下，像衢州新安發展這樣的股票脱穎而出，因為它們結合了良好的增長前景和高水平的內部投資，這通常可以表明對公司未來表現的信心。</p>
<h3>亞洲內部持股高的十大成長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>25%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Streamax Technology (SZSE:002970)</td>
<td>32.5%</td>
<td>33.1%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Phison Electronics (TPEX:8299)</td>
<td>10.8%</td>
<td>29.8%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>31.4%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>37.5%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>34.4%</td>
<td>53.7%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>55.2%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速成長的亞洲內部持股高的 620 只股票的完整列表。</p>
<p>下面我們重點介紹幾隻我們獨特篩選器中的最愛。</p>
<h2>衢州新安發展 (SHSE:600208)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 衢州新安發展有限公司在中國從事房地產開發和金融服務，市值為 347.1 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入來源包括中國的房地產開發和金融服務。</p>
<p><strong>內部持股：</strong> 17.2%</p>
<p>衢州新安發展有望實現顯著增長，預計年收入增長 47.6%，超過中國市場的平均水平。儘管最近銷售和淨收入有所下降，但預計公司將在三年內實現盈利，超越平均市場增長率。然而，由於經營現金流對債務的覆蓋不足以及預計的股本回報率僅為 4.7%，其財務健康狀況仍然令人擔憂。</p>
<ul>
<li>解鎖我們對衢州新安發展股票分析的全面見解，詳見本成長報告。</li>
<li>我們最近的估值報告指出，衢州新安發展股票在市場上可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eca9c479-dccf-4060-9041-07515f959162/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eca9c479-dccf-4060-9041-07515f959162/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:600208 截至 2026 年 1 月的收益和收入增長</p>
<h2>寧波三興醫療電氣有限公司 (SHSE:601567)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 寧波三興醫療電氣有限公司在中國及國際上製造和銷售電力分配產品，市值為 343.6 億人民幣。</p>
<p><strong>運營：</strong> 寧波三興醫療電氣有限公司通過製造和銷售電力分配產品在國內外產生收入。</p>
<p><strong>內部持股：</strong> 23.7%</p>
<p>寧波三興醫療電氣有限公司的交易價格低於其估計的公允價值，相較於同行提供了良好的相對價值。儘管股價波動較大，但預計收益將顯著增長，年增長率為 28.1%，超過更廣泛的中國市場增長率 27.9%。然而，最近的收益報告顯示淨收入同比下降至 15.2783 億人民幣，去年為 18.157 億人民幣。分析師預計股價將上漲 24%，儘管由於收益或自由現金流的覆蓋不足，股息的可持續性仍然存疑。</p>
<ul>
<li>點擊探索我們在寧波三興醫療電氣有限公司收益增長報告中的詳細發現。</li>
<li>根據我們最近的估值報告，寧波三興醫療電氣有限公司的交易價格似乎低於其估計價值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:601567 截至 2026 年 1 月的收益和收入增長</p>
<h2>概倫科技 (SHSE:688206)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 概倫科技有限公司從事電子設計自動化（EDA）工具的研究、設計和開發，市值為 172.5 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入主要來自 EDA 解決方案，金額為 4.5455 億人民幣。</p>
<p><strong>內部持股：</strong> 16.1%</p>
<p>概倫科技的內部持股顯著，最近的交易表明上海新合創收購了 5% 的股份。公司財務恢復顯著，報告淨收入為 4199 萬人民幣，而之前為虧損。預計收入年增長率為 19.7%，超過更廣泛的中國市場增長率 14.6%。儘管有這種增長潛力，但公司的股本回報率仍然較低，股價波動性高。</p>
<ul>
<li>深入瞭解概倫科技的完整分析未來增長報告。</li>
<li>根據我們最近的估值報告，概倫科技的交易價格似乎超出了其估計價值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/290ef310-da69-44c1-97a4-a1119e0111aa/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/290ef310-da69-44c1-97a4-a1119e0111aa/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688206 截至 2026 年 1 月的收益和收入增長</p>
<h2>關鍵要點</h2>
<ul>
<li>通過使用我們的篩選器，深入瞭解 620 家快速成長的亞洲內部持股高的公司。</li>
<li>尋找替代機會？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現的各個方面進行工作。最重要的是——它們的市值都在 100 億美元以下——仍然有機會提前佈局。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

三星醫療

概倫電子

<p>隨着全球市場波動，投資者正關注具有強勁增長潛力和高內部持股比例的亞洲公司。儘管財務健康狀況存在擔憂，衢州新安發展以 17.2% 的內部持股比例和預計 47.6% 的收入增長脱穎而出。其他值得注意的公司包括寧波三星醫療電氣，預計盈利增長 28.1%，以及概倫電子，內部持股比例為 16.1%，收入增長預測為 19.7%。這些公司反映出在市場波動中，投資者傾向於投資於內部信心顯著的企業</p>

<p>As global markets continue to experience fluctuations, with Asian indices showing resilience amid geopolitical tensions and economic shifts, investors are increasingly focusing on companies with strong growth potential and significant insider ownership. In this context, stocks like Quzhou Xin'an Development stand out as they combine promising growth prospects with high levels of insider investment, which can often signal confidence in a company's future performance.</p>
<div class="lb-trans"><p>隨着全球市場持續波動，亞洲指數在地緣政治緊張局勢和經濟變動中表現出韌性，投資者越來越關注具有強勁增長潛力和顯著內部持股的公司。在這種背景下，像衢州新安發展這樣的股票脱穎而出，因為它們結合了良好的增長前景和高水平的內部投資，這通常可以表明對公司未來表現的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亞洲內部持股高的十大成長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>25%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Streamax Technology (SZSE:002970)</td>
<td>32.5%</td>
<td>33.1%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Phison Electronics (TPEX:8299)</td>
<td>10.8%</td>
<td>29.8%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>31.4%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>37.5%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>34.4%</td>
<td>53.7%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>55.2%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>25%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Streamax Technology (SZSE:002970)</td>
<td>32.5%</td>
<td>33.1%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Phison Electronics (TPEX:8299)</td>
<td>10.8%</td>
<td>29.8%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>31.4%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>37.5%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>34.4%</td>
<td>53.7%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>55.2%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 620 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速成長的亞洲內部持股高的 620 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>下面我們重點介紹幾隻我們獨特篩選器中的最愛。</p>
</div><h2>Quzhou Xin'an Development (SHSE:600208)</h2>
<div class="lb-trans"><h2>衢州新安發展 (SHSE:600208)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Quzhou Xin'an Development Co., Ltd. operates in real estate development and financial services in China, with a market cap of CN¥34.71 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 衢州新安發展有限公司在中國從事房地產開發和金融服務，市值為 347.1 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include real estate development and financial services in China.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來源包括中國的房地產開發和金融服務。</p>
</div><p><strong>Insider Ownership:</strong> 17.2%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 17.2%</p>
</div><p>Quzhou Xin'an Development is poised for substantial growth, with revenue projected to increase by 47.6% annually, outpacing the Chinese market's average. Despite a recent decline in sales and net income, the company is expected to become profitable within three years, surpassing average market growth rates. However, its financial health remains a concern due to inadequate debt coverage by operating cash flow and a forecasted low return on equity of 4.7%.</p>
<div class="lb-trans"><p>衢州新安發展有望實現顯著增長，預計年收入增長 47.6%，超過中國市場的平均水平。儘管最近銷售和淨收入有所下降，但預計公司將在三年內實現盈利，超越平均市場增長率。然而，由於經營現金流對債務的覆蓋不足以及預計的股本回報率僅為 4.7%，其財務健康狀況仍然令人擔憂。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Quzhou Xin'an Development stock in this growth report.</li>
<li>Insights from our recent valuation report point to the potential overvaluation of Quzhou Xin'an Development shares in the market.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對衢州新安發展股票分析的全面見解，詳見本成長報告。</li>
<li>我們最近的估值報告指出，衢州新安發展股票在市場上可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eca9c479-dccf-4060-9041-07515f959162/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/eca9c479-dccf-4060-9041-07515f959162/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:600208 Earnings and Revenue Growth as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:600208 截至 2026 年 1 月的收益和收入增長</p>
</div><h2>Ningbo Sanxing Medical ElectricLtd (SHSE:601567)</h2>
<div class="lb-trans"><h2>寧波三興醫療電氣有限公司 (SHSE:601567)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Ningbo Sanxing Medical Electric Co., Ltd. manufactures and sells power distribution products in China and internationally, with a market cap of CN¥34.36 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 寧波三興醫療電氣有限公司在中國及國際上製造和銷售電力分配產品，市值為 343.6 億人民幣。</p>
</div><p><strong>Operations:</strong> Ningbo Sanxing Medical Electric Co., Ltd. generates its revenue through the manufacturing and sale of power distribution products both domestically and globally.</p>
<div class="lb-trans"><p><strong>運營：</strong> 寧波三興醫療電氣有限公司通過製造和銷售電力分配產品在國內外產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 23.7%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 23.7%</p>
</div><p>Ningbo Sanxing Medical Electric Ltd. is trading below its estimated fair value and offers good relative value compared to peers. Despite a volatile share price, earnings are forecasted to grow significantly at 28.1% annually, surpassing the broader Chinese market growth rate of 27.9%. However, recent earnings reports show a decline in net income to CNY 1,527.83 million from CNY 1,815.7 million year-on-year. Analysts expect a stock price rise by 24%, although dividend sustainability remains questionable due to inadequate coverage by earnings or free cash flows.</p>
<div class="lb-trans"><p>寧波三興醫療電氣有限公司的交易價格低於其估計的公允價值，相較於同行提供了良好的相對價值。儘管股價波動較大，但預計收益將顯著增長，年增長率為 28.1%，超過更廣泛的中國市場增長率 27.9%。然而，最近的收益報告顯示淨收入同比下降至 15.2783 億人民幣，去年為 18.157 億人民幣。分析師預計股價將上漲 24%，儘管由於收益或自由現金流的覆蓋不足，股息的可持續性仍然存疑。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Ningbo Sanxing Medical ElectricLtd's earnings growth report.</li>
<li>In light of our recent valuation report, it seems possible that Ningbo Sanxing Medical ElectricLtd is trading behind its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在寧波三興醫療電氣有限公司收益增長報告中的詳細發現。</li>
<li>根據我們最近的估值報告，寧波三興醫療電氣有限公司的交易價格似乎低於其估計價值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:601567 Earnings and Revenue Growth as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:601567 截至 2026 年 1 月的收益和收入增長</p>
</div><h2>Primarius Technologies (SHSE:688206)</h2>
<div class="lb-trans"><h2>概倫科技 (SHSE:688206)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Primarius Technologies Co., Ltd. is engaged in the research, design, and development of electronic design automation (EDA) tools both in China and internationally, with a market cap of CN¥17.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 概倫科技有限公司從事電子設計自動化（EDA）工具的研究、設計和開發，市值為 172.5 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from EDA Solutions, amounting to CN¥454.55 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自 EDA 解決方案，金額為 4.5455 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 16.1%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 16.1%</p>
</div><p>Primarius Technologies exhibits substantial insider ownership, with recent transactions indicating a 5% stake acquisition by Shanghai Xinhechuang. The company has shown impressive financial recovery, reporting a net income of CNY 41.99 million compared to a loss previously. Revenue is expected to grow at 19.7% annually, outpacing the broader Chinese market's growth rate of 14.6%. Despite this growth potential, the company's return on equity remains low and share price volatility is high.</p>
<div class="lb-trans"><p>概倫科技的內部持股顯著，最近的交易表明上海新合創收購了 5% 的股份。公司財務恢復顯著，報告淨收入為 4199 萬人民幣，而之前為虧損。預計收入年增長率為 19.7%，超過更廣泛的中國市場增長率 14.6%。儘管有這種增長潛力，但公司的股本回報率仍然較低，股價波動性高。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Primarius Technologies.</li>
<li>In light of our recent valuation report, it seems possible that Primarius Technologies is trading beyond its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>深入瞭解概倫科技的完整分析未來增長報告。</li>
<li>根據我們最近的估值報告，概倫科技的交易價格似乎超出了其估計價值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/290ef310-da69-44c1-97a4-a1119e0111aa/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/290ef310-da69-44c1-97a4-a1119e0111aa/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688206 Earnings and Revenue Growth as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688206 截至 2026 年 1 月的收益和收入增長</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Get an in-depth perspective on all 620 Fast Growing Asian Companies With High Insider Ownership by using our screener here.</li>
<li>Looking For Alternative Opportunities? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過使用我們的篩選器，深入瞭解 620 家快速成長的亞洲內部持股高的公司。</li>
<li>尋找替代機會？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現的各個方面進行工作。最重要的是——它們的市值都在 100 億美元以下——仍然有機會提前佈局。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

由衢州新安發展公司領導的亞洲增長型公司具有高內部持股比例